Correction to: J Exp Clin Cancer Res (2019) 38:105
https://doi.org/10.1186/s13046-019-1111-5
Anzeige
In the original publication of this article [1], the molecular weight of RBMS3 was incorrectly noted as 38 KDa within Fig, 1a, Fig. 2a and Fig. 2b. The figures have been updated to list the correct molecular weight of RBMS3 as 41 KDa.
Fig. 1
RBMS3 was downregulated in human breast tumors and correlated with poorer prognosis. a RBMS3 was downregulated in breast cancer cells. The expression levels of RBMS3 in breast cancer cell lines SKBR3, MDA-MB-231, MDA-MB-453, SUM-1315 and ZR75–1 were detected by Western blot and qRT-PCR, and the non-tumorigenic cell line MCF-10A were used as control. b RBMS3 expression was lower in breast cancer tissues. qRT-PCR and western blot were used to detect the expression of RBMS3 in breast cancer tissues and the corresponding adjacent tissues (Reviewer #1 comment 4). The expression of RBMS3 in breast cancer tissues were normalized to the corresponding adjacent tissues. c Expression of RBMS3 in the TCGA Breast Cancer (BRCA) database, including 1247 samples, p<0.001.(Reviewer #1 comment 2) (d) Kaplan-Meier overall survival curve exhibited patients with breast cancer expressing high (red) levels of RBMS3 had better prognosis than those low (black) levels of RBMS3. Including 3955 samples, P < 0.05 by log rank test (Reviewer #1 comment 2). The Affymetrix ID of RBMS3 is 206767_at. (Reviewer #2 comment 2) (e) RBMS3 was downregulated in the four subtypes of breast cancer compared to normal
Fig. 2
RBMS3 inhibited the migration invasion of breast cancer cells in vitro and in vivo. a, b SUM-1315 and MDA-MB-231 cell lines were respectively transfected with lentivirus to overexpress (RBMS3) or knocked down (sh-1, sh-2, sh-3) RBMS3 expression. Western blot and qRT-PCR were applied to verify transfection efficiency. c-j RBMS3 inhibited the invasion and migration of breast cancer cells. c, g, e, i Transwell experiment was used to detect the invasion and migration ability of SUM-1315 cells. The lower panel of each picture showed migrating and invading numbers of SUM-1315 cells. Transwell assay performed in MDA-MB-231 cells were analyzed as in Fig. 2d, h, f, and j. Scale bars, 50 μm. (Reviewer #1 comment 5) Data were shown as mean ± SEM, *P < 0.05. k RBMS3 inhibited the lung metastasis in breast cancer cells. Representative bioluminescence images of the mice and HE staining of lung section showed the sizes and numbers of lung colonization in the RBMS3-overexpressed group and the control group, respectively. Metastasis nodules plot was generated by the H&E-stained lung sections of nude mice (n = 9). Data were shown as mean ± SEM, *P < 0.05, **P<0.001 (Reviewer #1 comment 6). SCR = Scrambled control; Sh = Short hairpin; NC = Negative control
×
×
The authors sincerely apologize for the inconvenience caused to the readers.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.
Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.
Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
